AI in Drug Discovery Market

The The AI in drug discovery market is projected to grow from USD 5.09 billion in 2026 to USD 17.56 billion by 2031, at a CAGR of 28.1% during the forecast period. The market is primarily driven by the pharmaceutical industry’s increasing focus on reducing drug discovery timelines, lowering escalating R&D costs, and improving clinical success rates through artificial intelligence (AI)-enabled predictive modeling. The growing adoption of generative AI, graph neural networks, foundation models, and large biological datasets is transforming target identification, lead optimization, and candidate selection. In parallel, expanding collaborations between pharmaceutical companies, biotechnology firms, AI developers, and cloud technology providers are accelerating the commercialization of AI-driven discovery platforms. Increasing availability of multi-omics data, advancements in high-performance computing, and investments in precision medicine are further strengthening market growth. As pharmaceutical companies continue to integrate AI across the early-stage drug development workflow, demand for scalable AI platforms capable of combining computational chemistry, molecular simulation, and biological data analytics is expected to increase significantly over the forecast period.

NVIDIA Corporation (US), Schrödinger (US), Recursion (US), Insilico Medicine (Hong Kong), and Google (US) are among the major companies operating in the AI in drug discovery market. Strategic collaborations and continuous platform innovation remain the two most dominant competitive strategies shaping the AI in drug discovery market. Companies are increasingly partnering with pharmaceutical manufacturers, contract research organizations (CROs), academic institutions, and cloud infrastructure providers to accelerate target discovery, optimize lead generation, and validate AI-derived drug candidates. Technology providers such as NVIDIA, Google, Microsoft, and Schrödinger continue to strengthen their AI platforms through new product launches, foundation models, and integration of generative AI with molecular modeling, simulation, and high-performance computing.

To know about the assumptions considered for the study download the pdf brochure

A notable recent development highlighting this trend is Insilico Medicine’s strategic collaboration with Takeda, announced in July 2026, to leverage its Pharma.AI platform for discovering novel therapeutics across multiple disease areas. The agreement, valued at up to USD 600 million, reflects the growing confidence of leading pharmaceutical companies in AI-native drug discovery platforms and reinforces the increasing commercialization of AI-enabled drug discovery workflows.

NVIDIA Corporation (US)

NVIDIA Corporation has established itself as a foundational technology provider for AI-driven drug discovery by combining accelerated computing, generative AI, and domain-specific software platforms. The company’s strategy centers on enabling pharmaceutical and biotechnology organizations with scalable AI infrastructure through its BioNeMo platform, DGX systems, CUDA ecosystem, and cloud-based AI services. Its core competency lies in high-performance computing, AI model training, and molecular simulation, allowing researchers to accelerate protein structure prediction, molecular generation, and virtual screening workflows. It has strengthened its ecosystem through strategic collaborations with leading pharmaceutical companies, cloud service providers, and software developers while continuously expanding BioNeMo with foundation models designed specifically for life sciences. Rather than directly discovering therapeutics, it has positioned itself as the enabling technology layer powering next-generation AI drug discovery platforms across the industry, creating strong vertical integration between computing infrastructure, AI software, and life sciences applications.

Schrödinger, Inc. (US)

Schrödinger, Inc. differentiates itself through its integrated computational chemistry platform that combines physics-based molecular simulations with machine learning and AI-driven drug design. The company’s strategy focuses on delivering end-to-end computational solutions that improve decision-making across hit identification, lead optimization, and candidate selection while simultaneously advancing its own proprietary drug pipeline. Its core competency lies in its highly validated molecular modeling software, predictive physics-based algorithms, and deep expertise in computational chemistry. It continues to expand its market presence through strategic collaborations with global pharmaceutical companies and biotechnology firms, enabling partners to improve R&D productivity while reducing experimental costs. Its vertically integrated business model, combining software licensing with internal therapeutic development, provides a differentiated competitive position by continuously validating its technology through commercial partnerships as well as proprietary drug discovery programs.

Market Ranking

NVIDIA Corporation, Schrödinger, Recursion, Insilico Medicine, and Google represent the strongest competitive positions within the AI in drug discovery market, each addressing different layers of the drug discovery value chain. NVIDIA Corporation has become the preferred AI computing and software platform provider through BioNeMo and its accelerated computing ecosystem, supporting large-scale model development across pharmaceutical organizations. Schrödinger has established leadership in computational chemistry and molecular simulation, with a mature software platform adopted by leading biopharmaceutical companies worldwide. Recursion combines one of the industry’s largest proprietary biological imaging datasets with advanced machine learning to drive end-to-end drug discovery and therapeutic development, further strengthened through strategic collaborations and high-throughput experimental capabilities. Insilico Medicine has built a comprehensive generative AI platform spanning target discovery, molecular generation, and clinical candidate development, demonstrating commercial maturity through multiple pharmaceutical partnerships and internally developed assets. Google continues to influence the market through its AI research capabilities, cloud infrastructure, and advanced protein modeling technologies, providing foundational technologies that support AI-enabled drug discovery across academia, biotechnology companies, and pharmaceutical manufacturers. Together, these companies shape technology innovation, commercial adoption, and competitive dynamics within the rapidly evolving Artificial intelligence in drug discovery ecosystem.

Related Reports:

AI in Drug Discovery Market by Process (Target, Lead), Use Case (Repurposing, DE Novo Drug Design [Vaccine] Optimization, Disease Understanding, PK/PD), Therapy (Cancer, CNS), Tool (DL [CNN, GAN]), End User - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]